HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

EW

Edwards Lifesciences Corporation (S&P 500)

Healthcare — Medical Devices

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Buy 1.6 / 5 26 analysts
$85.19
$-1.13 (-1.31%)
Target: $100.96 (18.5%)

Price History

52-Week Range
Sign in to add EW to a watchlist or set price alerts.

Fundamentals

Market Cap$49.10B
P/E Ratio (TTM)50.71
Forward P/E25.23
EPS (TTM)$1.68
Dividend Yield-
Profit Margin15.43%
Revenue Growth13.60%
ROE9.18%
Debt/Equity6.57
Recommendation Buy 1.6
Analyst Target$100.96
Analysts26
Next Earnings Jul 23, 2026 AMC
Indexes S&P 500

Technical Indicators

RSI (14)52.8
Beta0.85
SMA 20$87.16
SMA 40$89.09
52-Week High$96.29
52-Week Low$72.30
50-Day Avg$88.44
200-Day Avg$85.11
Avg Volume$3.87M
Volume$3.08M

Performance Analysis

NEUTRAL

EW presents a mixed picture with both positive and negative indicators.

~ Trading at 54% of its 52-week range.
~ RSI at 52.8 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- P/E of 50.7 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 13.6% year-over-year.
+ Wall Street consensus is "Buy" from 26 analysts.
+ Average analyst target of $100.96 implies 18.5% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:01 UTC

Back to Screener Export Report